We serve Chemical Name:2-(3-methylbutoxy)benzaldehyde CAS:81995-28-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(3-methylbutoxy)benzaldehyde
CAS.NO:81995-28-0
Synonyms:2-isopentyloxy-benzaldehyde
Molecular Formula:C12H16O2
Molecular Weight:192.25400
HS Code:2912499000
Physical and Chemical Properties:
Melting point:N/A
Boiling point:291.1ºC at 760 mmHg
Density:1.003g/cm3
Index of Refraction:1.519
PSA:26.30000
Exact Mass:192.11500
LogP:2.92400
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-isopentyloxy-benzaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-isopentyloxy-benzaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-isopentyloxy-benzaldehyde Use and application,2-isopentyloxy-benzaldehyde technical grade,usp/ep/jp grade.
Related News: Dr. John K. Westwick, CEO of Resonant, added ��Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates. 2-(3-methylbutoxy)benzaldehyde manufacturer Three more patients have been confirmed infected with coronavirus in South Korea, bringing the country’s total to 15, the South Korean Centers for Disease Control and Prevention (KCDC) announced in a press release. 2-(3-methylbutoxy)benzaldehyde supplier Novavax, a Maryland biotechnology company that has struggled mightily with delays in developing its coronavirus vaccine, announced Monday that its two-shot regimen was over 90% effective overall in a trial that unfolded even as more contagious variants emerged. 2-(3-methylbutoxy)benzaldehyde vendor The second is known as the excipient, which is the inactive substance that serves as the vehicle for the API itself. 2-(3-methylbutoxy)benzaldehyde factory Dr. John K. Westwick, CEO of Resonant, added ��Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates.